Biophysical characterization of fibrinogen Caracas I with an Aα-chain truncation at Aα-466 Ser: Identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 4, 2004, Pages 285-293

  Marchi, Rita ^a,b   Meyer, Michael ^c   De Bosch, Norma ^d   Soria, Jeannette ^e   Arocha Piñango, Carmen Luisa ^a   Weisel, John W ^b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF APPLIED SCIENCES JENA   (Germany)

^d Banco Munic Sangre Distrito F   (Venezuela)

^e HÔTEL DIEU   (France)

Author keywords

Dysfibrinogenemia; Fibrin fiber; Lateral aggregation; Truncated C terminal A chain

Indexed keywords

FIBRIN; FIBRINOGEN; SERINE;

ALPHA CHAIN; ARTICLE; BLOOD CLOT; CARBOXY TERMINAL SEQUENCE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DENSITY; DYSFIBRINOGENEMIA; FIBER; FIBRINOGEN CARACAS 1; FLOW KINETICS; G4731T GENE; GENE; GENE IDENTIFICATION; HETEROZYGOSITY; HUMAN; MEASUREMENT; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PATIENT; PLASMA; POLYMERIZATION; POROSITY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PURIFICATION; RIGIDITY; SCANNING ELECTRON MICROSCOPY; STOP CODON; STRUCTURE ANALYSIS; TURBIDITY; VISCOELASTICITY;

BIOMECHANICS; BLOOD COAGULATION; COAGULATION PROTEIN DISORDERS; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FIBRIN; FIBRINOGEN; FIBRINOGENS, ABNORMAL; HUMANS; MICROSCOPY, ELECTRON, SCANNING; POROSITY; SEQUENCE DELETION;

EID: 2942592720     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200406000-00001     Document Type: Article

References (51)

1. Weisel JW, Phillips GN, Cohen C. A model from electron microscopy for the molecular structure of fibrinogen and fibrin. Nature 1981; 289:263-267.
2. Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: domains and sequences. Science 1985; 230:1388-1391.
3. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its cross-linked counterpart from fibrin. Nature (London) 1997; 389:455-462.
4. Veklich YI, Gorkun OV, Medved' LV, Nieuwenhuizen W, Weisel JW. Carboxy-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 1993; 268:13577-13585.
5. Doolittle RF. Fibrinogen and fibrin. In: Bloom AL, Thomas DP (editors): Haemostasis and thrombosis. London: Churchill Livingston, 1981, pp. 163-191.
6. Doolittle RF. Structural aspects of the fibrinogen to fibrin conversion. Adv Protein Chem 1973; 27:1-109.
7. Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275:501-505.
8. Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77:1374-1378.
9. Mosesson MW. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinolysis 1997; 8:257-267.
10. Gorkun OV, Veklich YI, Medved' LV, Henschen AH, Weisel JW. Role of the αC domains of fibrin in clot formation. Biochemistry 1994; 33:6986-6997.
11. Cottrell BA, Strong DD, Watt KWK, Doolittle RF. Amino acid studies on the α chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979; 18:5405-5410.
12. a fibrin cross-linking. J Biol Chem 1996; 271:19288-19297.
13. Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology 1973; 10:29-42.
14. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71:1336-1341.
15. Gladner JA, Nossal R. Effects of cross-linking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30:273-288.
16. 2-plasmin inhibitor. J Biol Chem 1986; 261:15591-15595.
17. 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65:290-297.
18. 2- plasmin inhibitor to fibrin in inhibition or fibrinolysis and in hemostasis. J Clin Invest 1982; 69:536-542.
19. Medved' LV, Gorkun OV, Manyakov VF, Belitser VA. The role of fibrinogen αC-domains in the fibrin assembly process. FEBS 1985; 181:109-112.
20. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distint adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58:945-953.
21. Collen A, Maas A, Kooistra T, Lupu F, Grimbergen J, Haad FJ, et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aα-chain, alters endothelial capillary tube formation. Blood 2001; 97:973-980.
22. Lefebvre P, Velasco PT, Dear A, Lounes KG, Lord ST, Brennan SO, et al. Severe hypodysfibrinogenemia in compound heterozygotes of fibrinogen AαIVS4+1G>T mutation and an AαGln328 truncation (Fibrinogen Keokuk). Blood 2004; 103:2571-2576.
23. Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys 461 AAA → Stop TAA). Blood 1992; 80:1972-1979.
24. Ridgway HJ, Brennan SO, Gibbons S, George PM. Fibrinogen Lincoln: a new truncated α chain variant with delayed clotting. Br J Haematol 1996; 93:177-184.
25. Furlan M, Steinmann C, Jungo M, Lämmle B. Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα-chains. Blood Coagul Fibrinolysis 1996; 7:331-335.
26. Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major α chain truncation associated with severe hypofibrinogenemia and recurrent miscarriage. Br J Haematol 1997; 98:632-639.
27. Margaglione M, Vecchione G, Santacroce R, D'Angelo F, Casetta B, Papa ML, et al. A Frameshift mutation in the human fibrinogen Aα-chain gene (Aα[499]Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo. Thromb Haemost 2001; 86:1483-1488.
28. Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia. J Clin Invest 1999; 103:215-218.
29. Fellowes AP, Brennan SO, Holme R, Stormorken H, Brosstad FR, George PM. Homozygous truncation of the Aα chain within the coiled coil causes congenital afibrinogenemia. Blood 2000; 96:773-775.
30. Brennan SO, Fellowes AP, George PM. Molecular mechanisms of hypo- and afibrinogenemia. Ann NY Acad Sci 2001; 936:91-100.
31. de Bosch NB, Arocha-Piñango CL, Soria J, Soria C, Rodriguez A, Rodriguez S. An abnormal fibrinogen in a Venezuelan family. Thromb Res 1977; 1:253-265.
32. Laemmli UK. Cleavage of structurals proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
33. Marchi R, Lundberg U, de Bosch NB, Arocha-Piñango CL. Fibrinogen Caracas I: a dysfibrinogenemia with a hemorrhagic diathesis associated with diminished fibrin fiber diameter and reduced fibrin gel porosity. Blood Coagul Fibrinolysis 1998; 9:733-739.
34. Kazal LA, Amsel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113:989-944.
35. Godal HC, Gravem K, Brosstad F, Nyvold N. Quantitation of factor XIII by SDS polyacrylamide gel electrophoresis. Thromb Res 1984; 35:577-582.
36. O'Farrell PH. High resolution two-bidimensional electrophoresis of proteins. J Biol Chem 1975; 250:4007-4021.
37. Marchi R, Mirshahi SS, Collet JP, Mirshahi M, Soria C, Mishal Z, et al. Thrombotic dysfibrinogenemia: fibrinogen Caracas V. Relation between very tight fibrin network and defective clot degradability. Thromb Res 2000; 99:187-193.
38. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyck R, Åslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochem Biophys Acta 1989; 997:96-110.
39. Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell WR. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem 1988; 263:15056-15063.
40. Dhall TZ, Bryce AJW, Dhall DP. Effects of Dextran on the molecular structure and tensile behaviour of human fibrinogen. Thromb Haemost 1976; 35:737-745.
41. Nair CH, Shats EA. Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to cross-linking. Thromb Res 1997; 88:381-387.
42. Janmey PA. A torsion pendulum for measurement of the viscoelasticity of biopolymers and its application to actin networks. J Biochem Biophys Methods 1991; 22:41-53.
43. Fuchs G, Egbring R, Havermann. Fibrinogen Marburg. A new genetic variant of fibrinogen. Blut 1977; 34:107-118.
44. Hartert H. Blutgerinnungsstudien mit der thrombelastographie, einem neuen untersuchungsverfahren. Klin Wschs 1948; 26:577-583.
45. Sobel JH, Trakht I, Wu QW, Rudchenko S, Egbring R. α-chain cross-linking in fibrin(ogen) Marburg. Blood 1995; 86:989-1000.
46. Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins. VIII. Conversion of human fibrinogen to fibrin under various conditions. Am Chem Soc J 1947; 69:388-400.
47. Nair CH, Shah GA, Dhall DP. Effect of temperature, pH and ionic strength and composition of fibrin network structure and its development. Thromb Res 1986; 42:809-816.
48. Müller MF, Bale MD, Ferry JD. Structure and mechanical properties of fibrin networks. In: Müller-Berghaus G, Scheefers-Borchel U, Selmayr E, Henschen A, (editors): Fibrinogen and its derivatives. Biochemistry, physiology and pathophysiology. Excerpta Medica, Amsterdam. 1986; pp. 81-85.
49. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77:2813-2826.
50. Gorkun OV, Veklich YI, Medved' LV, Henschen AH, Weisel JW. Role of the αC domains of fibrin in clot formation. Biochemistry 1994; 33:6986-6997.
51. Weisel JW, Medved L. The structure and function of the αC domains of fibrinogen. Ann NY Acad Sci 2001; 936:312-327.